

Case-Control Set 1

Mullins DN, Crawford EL, Khuder SA, Hernandez DA, Yoon Y, Willey JC. CEBPG transcription factor correlates with antioxidant and DNA repair genes in normal bronchial epithelial cells but not in individuals with bronchogenic carcinoma. BMC Cancer 2005; 5:141.

LC = Lung Cancer
 NLC = non-Lung Cancer
 ND = No data
 *** Units are in Log base 10 transformed target transcript molecules per 10⁶ ACTB transcript molecules

SUBJECT#	Diagnosis	CAT	CEBPG	E2F1	ERCC4	ERCC5	GPX1	GPX3	GSTM3	GSTP1	GSTT1	GSTZ1	MGST1	SOD1	XRCC1	Risk Test Value (RTV)	Age (Years:Gender)	Histology	Smoking Hx (Pack Years)	Race	
34	LC	4.83	4.23	2.76	3.18	5.08	5.94	3.49	2.71	6.26	ND	3.28	4.79	5.46	4.75	7	80	M	NSCLC	40	W
71	LC	4.98	4.08	3.11	2.38	5.34	5.94	4.11	3.34	6.83	ND	3.40	5.61	5.88	5.75	11	63	M	NSCLC	100	W
85	LC	4.41	3.99	2.94	2.59	4.36	5.36	3.04	3.61	6.08	4.00	2.91	4.68	5.18	4.26	10	73	F	SQ	100	W
88	LC	4.49	3.60	2.62	2.56	4.59	5.11	3.18	3.04	5.84	ND	2.75	4.38	5.28	4.20	14	85	M	SQ	75	W
99	LC	5.32	4.52	3.41	2.97	5.15	5.95	3.32	3.74	6.98	3.83	3.90	5.08	5.97	4.67	9	63	M	NSCLC	45	W
118	LC	4.38	4.08	2.45	3.08	4.23	4.90	3.58	3.68	6.23	3.60	2.65	4.64	5.23	3.79	11	72	M	SQ	30	W
146	LC	4.49	4.08	2.36	2.43	4.79	5.61	4.46	2.67	6.30	3.85	4.20	4.82	5.23	4.81	11	64	F	SCLC	45	W
147	LC	4.79	4.11	ND	3.04	4.26	5.61	3.40	2.86	5.94	3.23	3.11	4.36	5.81	4.87	8	76	M	SCLC	75	W
158	LC	4.34	3.94	2.28	2.18	4.11	4.41	3.41	3.67	6.36	3.46	3.08	4.36	4.57	4.36	12	88	M	SCLC	115.5	W
167	LC	4.95	3.96	2.62	2.45	4.61	5.28	3.40	3.26	6.38	4.15	3.36	4.98	5.60	4.45	7	60	F	NSCLC	50	W
171	LC	5.72	4.59	3.51	2.80	5.20	6.20	3.23	3.60	6.89	3.78	3.81	5.40	6.15	4.78	9	67	M	SCLC	100	W
191	LC	4.30	4.38	2.18	2.53	4.08	5.65	3.28	2.40	6.23	3.56	2.75	4.32	5.20	4.32	12	75	M	SQ	54	W
211	LC	4.92	4.04	2.81	2.51	4.96	5.78	4.23	2.11	7.00	3.74	3.61	4.38	5.85	4.92	11	71	M	SQ	50	W
212	LC	4.53	4.45	2.78	2.48	4.56	4.81	3.20	3.04	6.60	3.91	2.98	4.88	4.97	4.56	10	65	M	SQ	67.5	W
247	LC	4.89	3.88	2.81	3.43	4.11	5.36	2.30	3.32	6.11	3.85	3.04	4.38	5.11	4.04	12	75	F	SQ	50	W
255	LC	5.04	4.04	2.79	3.08	5.58	6.11	3.86	3.40	6.45	4.58	3.91	5.04	6.45	5.00	11	60	F	NSCLC	30	W
259	LC	4.67	3.81	2.71	2.58	4.90	6.48	3.77	3.85	6.96	3.71	3.71	5.04	5.70	4.32	8	68	M	CS	137.5	W
271	LC	4.96	3.82	3.15	ND	5.18	5.87	2.98	3.41	6.38	3.57	3.49	4.85	5.80	4.48	7	58	M	AC	94.5	W
287	LC	4.67	4.04	1.98	2.04	4.61	5.76	3.94	3.36	6.28	4.18	2.80	4.94	5.08	4.52	8	65	F	NSCLC	50	W
300	LC	4.53	3.64	2.61	3.00	4.41	5.43	3.18	3.70	6.57	3.85	3.28	4.83	5.51	4.11	10	56	M	SQ	34	W
306	LC	4.57	3.83	2.69	2.51	4.61	5.62	2.30	3.36	6.34	ND	3.68	4.75	6.04	4.28	9	46	M	SQ	30	W
314	LC	4.72	3.97	2.68	2.72	4.49	5.20	3.57	3.04	6.08	2.28	3.18	4.43	5.43	4.53	9	69	F	BC	0	W
329	LC	4.90	3.54	2.38	ND	5.18	5.36	3.95	3.72	6.86	3.89	3.15	4.76	5.95	4.68	11	76	F	PD	38	W
335	LC	4.68	3.57	3.34	2.49	4.52	5.61	3.81	3.85	6.63	2.26	3.85	4.84	5.72	4.64	7	75	M	SCLC	58	A.A.
B3	LC	4.53	3.97	2.15	2.45	4.61	5.60	3.51	2.58	6.20	3.89	3.26	4.26	5.41	4.23	10	63	M	SQ	60	W
63	NLC	4.30	3.81	2.43	2.04	4.63	5.92	3.18	3.59	6.28	ND	3.49	5.23	5.20	4.32	9	77	M		75	W
64	NLC	4.40	4.23	3.30	1.91	5.30	5.64	2.49	3.41	6.54	3.81	3.30	5.20	5.81	4.62	5	47	F		45	W
136	NLC	3.46	3.32	2.85	1.75	4.28	5.30	2.72	3.34	5.72	ND	2.95	4.51	4.72	3.64	11	38	M		25	A.A.
139	NLC	5.79	4.53	4.36	3.59	5.66	6.26	3.51	3.92	7.51	ND	4.45	5.92	6.34	5.20	12	44	F		17.5	W
150	NLC	4.54	3.87	2.20	2.84	4.86	5.32	3.45	3.04	6.18	ND	3.49	4.49	5.30	4.49	7	70	F		45	W
156	NLC	4.18	4.08	2.88	2.46	4.48	5.68	3.59	3.81	6.46	ND	3.69	4.76	5.11	4.40	7	46	F		0	A.A.
157	NLC	5.54	4.61	3.49	3.20	5.32	6.38	3.30	3.52	7.26	3.93	3.56	5.56	6.26	5.23	9	60	M		100	W
194	NLC	4.65	4.32	2.46	2.64	4.95	5.73	3.60	3.04	6.89	3.89	3.51	4.98	5.76	5.38	5	57	M		3	W
210	NLC	4.88	4.32	2.88	2.89	4.86	5.51	3.52	3.41	6.59	3.26	3.57	4.86	5.52	4.46	2	40	M		34	W
257	NLC	5.00	4.26	2.43	2.88	4.87	5.80	3.40	2.08	6.45	3.94	3.46	4.36	5.08	4.69	6	69	F		20	W
261	NLC	4.64	4.11	2.40	2.66	5.11	5.88	3.67	3.87	6.49	3.18	3.26	5.08	5.65	4.86	7	73	F		0	W
282	NLC	4.61	4.08	2.73	2.91	4.60	5.66	3.40	3.36	6.28	4.18	3.11	4.81	5.65	4.49	5	83	F		60	W
285	NLC	4.57	3.64	3.40	3.89	4.20	5.63	3.72	2.79	6.54	3.86	3.96	4.48	5.36	4.30	7	69	F		0	W
296	NLC	4.84	4.00	3.00	2.23	4.85	5.91	3.18	3.61	6.56	3.91	3.65	5.30	5.73	4.72	3	43	F		20	W
305	NLC	4.30	2.96	2.79	2.45	4.11	5.15	2.81	3.51	6.20	ND	2.84	4.61	5.26	3.76	12	50	F		40	W
315	NLC	4.67	4.11	3.08	3.38	4.79	5.62	3.88	3.49	6.90	3.86	3.63	4.86	5.65	4.58	3	64	M		0	W
330	NLC	4.56	3.38	2.60	3.23	4.45	5.08	3.30	3.54	6.04	1.49	3.11	4.46	5.36	4.23	10	39	M		0	W
331	NLC	4.93	4.11	2.90	2.81	4.79	5.79	3.53	3.56	6.86	4.00	3.26	5.08	6.11	4.76	4	68	F		0	N/A
334	NLC	4.89	3.79	3.04	3.11	4.71	5.81	3.60	4.23	6.57	3.66	3.48	4.83	5.77	4.41	4	51	M		50	W
336	NLC	4.95	3.92	3.45	3.49	4.98	5.67	3.43	3.20	6.53	4.08	3.92	4.79	5.73	5.08	4	31	F		0	W
337	NLC	4.81	3.97	3.04	3.11	4.62	5.45	3.45	3.63	6.18	3.72	3.75	4.69	5.52	4.64	7	32	M		22	N/A
339	NLC	4.70	3.51	2.72	2.89	4.51	5.49	4.20	3.04	6.54	3.82	3.30	4.82	5.38	4.34	7	59	M		50	W
361	NLC	4.83	4.40	2.83	3.45	4.67	5.57	2.92	3.11	6.89	3.49	3.43	4.68	5.81	4.89	7	73	F		0	H
363	NLC	4.88	4.23	3.15	2.86	4.86	5.79	3.43	3.30	6.91	4.00	3.38	4.99	5.65	4.56	2	50	M		20	A.A.

Risk Test Value (RTV) as determined in the methods portion of this paper; NSCLC = Non-Small Cell Lung Cancer; SQ = Squamous Carcinoma; SCLC = Small Cell Lung Cancer; BC = Bronchogenic carcinoma histology not specified; AC = Adenocarcinoma; NS = Non-smoker; W = Caucasian; AA = African-American; H = Hispanic